Lyell Immunopharma Quote - LYEL | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Lyell Immunopharma Inc (LYEL) Share Price

Lyell Immunopharma Inc (LYEL)

2.05

-0.03

(-1.44%)

Closed 23 June 6:00AM

Delayed by 15 minutes

2.05

-0.02

(-0.97%)

After Hours: 7:12AM

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Current Price

2.05

Bid

2.07

Offer

2.71

Volume

1,953,795

2.03 Day's Range 2.14

1.32 52 Week Range 3.41

Market Cap

Previous Close

2.08

Open

2.14

Last Trade

Last Trade Time

Financial Volume

US$ 4,055,473

VWAP

2.0757

Average Volume (3m)

791,708

Shares Outstanding

254,939,222

Dividend Yield

-

PE Ratio

-2.25

Earnings Per Share (EPS)

-0.92

Revenue

2.92M

Net Profit

-234.63M

Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

lyell.com

Headquarters

Dover, Delaware, USA

Founded

1970

Lyell Immunopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LYEL. The last closing price for Lyell Immunopharma was US$2.08. Over the last year, Lyell Immunopharma shares have traded in a share price range of US$ 1.32 to US$ 3.41.

Lyell Immunopharma currently has 254,939,222 shares in issue. The market capitalisation of Lyell Immunopharma is US$527.72 million. Lyell Immunopharma has a price to earnings ratio (PE ratio) of -2.25.

Form 8-K - Current report

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from...

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

Form 8-K - Current report

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for LYL845 for the treatment of melanomaExpect to...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.48	-18.9723320158	2.53	2.56	2.03	474662	2.18724803	CS
4	-0.68	-24.9084249084	2.73	2.85	2.03	664123	2.53203457	CS
12	-0.22	-9.69162995595	2.27	3.145	2.01	791708	2.49588437	CS
26	0.01	0.490196078431	2.04	3.2556	1.69	905215	2.28428921	CS
52	-0.95	-31.6666666667	3	3.41	1.32	927786	2.20819727	CS
156	-14.05	-87.2670807453	16.1	19.84	1.32	927070	4.65055327	CS
260	-16.7	-89.0666666667	18.75	19.84	1.32	929362	4.71247552	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ME1OEMelodiol Global Health Ltd	AUD 0.006 (100.00%)	34
K2FK2fly Limited	AUD 0.1825 (82.50%)	2.49M
PRXProdigy Gold NL	AUD 0.003 (50.00%)	100.11k
ARVOCArtemis Resources Limited	AUD 0.003 (50.00%)	1.05M
MTBMount Burgess Mining Nl	AUD 0.0015 (50.00%)	5.38k
BNROBulletin Resources Limited	AUD 0.001 (-66.67%)	100k
FRSOAForrestania Resources Ltd	AUD 0.006 (-57.14%)	26k
GGEOAGrand Gulf Energy Limited	AUD 0.001 (-50.00%)	2.18M
D2OOADuxton Water Limited	AUD 0.021 (-47.50%)	4.5k
CT1Constellation Technologies Limited	AUD 0.002 (-33.33%)	50.02k
REDRed 5 Limited	AUD 0.4175 (3.09%)	135.31M
BGLBellevue Gold Limited	AUD 1.835 (-1.34%)	81.32M
NICNickel Industries Ltd	AUD 0.825 (-3.23%)	62.62M
S32South32 Limited	AUD 3.74 (1.77%)	56.22M
CXOCore Lithium Ltd	AUD 0.0855 (-6.04%)	56.06M

jondoeuk

jondoeuk 1 week ago

(OT) Dr Restifo is Co-founder and Chief Scientist at Marble Therapeutics. From this: ''At Marble Therapeutics, he is working to figure out how to rewind the epigenetic clock on these cells, using any means possible. The company started out with a focus on skin rejuvenation, adds CEO Denitsa Milanova, but expanded to also work on adoptive cell therapy to prove their platform works.'' https://web.archive.org/web/20231218233715/https://www.nature.com/articles/d41573-023-00206-6

They have a license for TIL plus a neoantigen vaccine https://www.federalregister.gov/documents/2024/02/07/2024-02491/prospective-grant-of-an-exclusive-patent-license-vaccine-augmented-adoptive-cell-therapy-for-the

Preclinical data on the vaccine https://jitc.bmj.com/content/11/Suppl_1/A418

🎯 1 👍️ 1

glenn1919

glenn1919 2 months ago

LYEL.....................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 2 months ago

LYEL active in the Gaucho session

jondoeuk

jondoeuk 3 months ago

Tempting but I will remain on the sidelines.

Monksdream

Monksdream 3 months ago

glenn1919

glenn1919 3 months ago

LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

jondoeuk

jondoeuk 8 months ago

They could be working on this https://ash.confex.com/ash/2023/webprogram/Paper182417.html

jondoeuk

jondoeuk 9 months ago

Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html

Monksdream

Monksdream 9 months ago

LYEL new 52 week low

jondoeuk

jondoeuk 1 year ago

LYL119 https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=13739

jondoeuk

jondoeuk 1 year ago

Preclinical data from another group (LYL119 will be NR4A3-deficient) https://www.biorxiv.org/content/10.1101/2023.04.21.537841v1.full

glenn1919

glenn1919 1 year ago

LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

jondoeuk

jondoeuk 2 years ago

The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.

jondoeuk

jondoeuk 2 years ago

SITC titles

NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology

NY1972

NY1972 2 years ago

recent technical advances using culture conditions with IL-7/IL-15 and
the addition of IL-21 may enhance the enrichment for TSCM cells
in the final CART product (74–76), which can be further increased
with the addition of drugs blocking T-cell differentiation, such as
glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products
have not been developed so far. Recently, a few CART19 clinical
trials for DLBCL have been conducted in which CART products
were manufactured from CD62L+ isolated T cells to generate
cellular products enriched for TCM cells (21, 78); however, due to
prolonged culture conditions, enrichment for TSCM and TCM
subsets in the infused product could not be demonstrated

https://www.frontiersin.org/articles/10.3389/fimmu.2022.904497/full

jondoeuk

jondoeuk 2 years ago

The AEs from the LD chemo*. I expect more data (dose expansion is ongoing) from them at ASH. As for NVS, a pivotal trial is planned and DL2 (12.5M) is the recommended dose.

* Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor

NY1972

NY1972 2 years ago

Thanks for the link.
Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%

Compared to T-Charge
http://www.koreabiomed.com/news/articleView.html?idxno=12767

jondoeuk

jondoeuk 2 years ago

For Epi-R, they use media with high concentrations of potassium (as well as multiple cytokines). As for that, T-Charge or BE, I think a product with mostly ''stem-like'' cells and additional edits will be needed. But it doesn't have to be the latter, as shRNA can be used. Here are some clinical data on an anti-CD19 CAR-T with knock-down of both PD-1 and TIGIT https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522

NY1972

NY1972 2 years ago

Which will perform better ? BE with 7,8 edits on many genes, Epi secret sauce
or T-Charge which seems to add a CAR only to starting material in order to retain CD4/CD8 ratio.
YTB323 CAR-T cell products generated via this novel expansionless manufacturing process retained the immunophenotype of the input leukapheresis materia

jondoeuk

jondoeuk 2 years ago

That depends. Typically, the more the cells expand during manufacturing, the more they differentiate. In the case of ALLO, it seems most are effector memory (manufacturing time is ~19 days and there are a number of steps involved). LYEL refer to this as the expansion/quality paradox. With Epi-R, they have shown they can expand TCR-T cells up to 18 billion by day ten. In addition, these cells are over 94% viable and maintain their ''stem-like'' qualities.

NY1972

NY1972 2 years ago

Do you need Epigenetic Reprogramming if pts can be treated with healthy, young donor T cells?

jondoeuk

jondoeuk 2 years ago

ISSCR poster https://ir.lyell.com/static-files/971404cb-28eb-46fc-839f-b20735899373

jondoeuk

jondoeuk 2 years ago

Posters https://ir.lyell.com/static-files/d3a3d05c-1b39-4092-bf82-a486933bc268

https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4

jondoeuk

jondoeuk 2 years ago

1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2014

661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597

jondoeuk

jondoeuk 2 years ago

GSK has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses Epi-R.

jondoeuk

jondoeuk 2 years ago

AACR poster https://ir.lyell.com/static-files/ad2cd8dc-b41b-4536-a854-c4d1246422e6

jondoeuk

jondoeuk 2 years ago

The PhI (n=54) of LYL797 has now been listed. The dose-escalation phase (TNBC only) will investigate four dose levels to determine the recommended RP2D. The dose expansion will enroll both TNBC and NSCLC.

jondoeuk

jondoeuk 3 years ago

A new review https://www.sciencedirect.com/science/article/pii/S0952791521001278

jondoeuk

jondoeuk 3 years ago

Morgan Stanley webcast https://morganstanley.webcasts.com/viewer/event.jsp?ei=1488969&tp_key=3cedc4a917

jondoeuk

jondoeuk 3 years ago

New deck https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583

Lyell Immunopharma

Ggb Tf 1,875% Lg26 Eur

Casino Guichard Perrachon

Blue Thunder Mining (PK)

CryptoNeur Network foundation

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions